Journal
DRUG DISCOVERY TODAY
Volume 18, Issue 23-24, Pages 1256-1262Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2013.07.003
Keywords
-
Categories
Ask authors/readers for more resources
The non-mevalonate pathway constitutes a source of novel drug targets. This biosynthetic route is essential for pathogens but is absent in humans. Our systematic evaluation of the druggability of all enzymes provides a convenient way of selecting targets that should be most easily inhibited by small-molecule drugs. We found that not every target is equally druggable and we identified novel, druggable, potentially allosteric sites. These results should accelerate the development of anti-infective drugs with a novel mode of action, which are needed ever more urgently in light of the rapid emergence of drug-resistant strains.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available